Open Access<p>Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab</p>
Author(s) -
YiQun Che,
Yue Zhang,
Di Wang,
Huiying Liu,
Di Shen,
Yang Luo
Publication year - 2019
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s212610
Subject(s) - medicine , trastuzumab , hazard ratio , oncology , proportional hazards model , lactate dehydrogenase , breast cancer , metastatic breast cancer , univariate analysis , gastroenterology , lymphocyte , cancer , multivariate analysis , confidence interval , biochemistry , chemistry , enzyme
Despite selection based on human epidermal growth factor receptor 2 (HER2) overexpression, not all HER2-positive patients benefit from trastuzumab therapy. Recent reports indicate that trastuzumab treatment failure may be associated with immune system dysfunction. We examined the prognostic relevance of the absolute lymphocyte count (ALC) in patients with HER2-positive metastatic breast cancer (MBC) who received trastuzumab combined with chemotherapy.